MTC and Riken developed technology to produce Astatine in large quantities.

A joint research team consisting of Takashi Kurihara, Shingo Nakamura, and Hiroshi Arata of the Technical Development Division of MTC, and Hiromitsu Haba, head of the Nuclear Chemistry Group, RIKEN Nishina Center for Accelerator-Based Science etc. (all are visiting engineers in the Nuclear Chemistry Group, RIKEN Nishina Center for Accelerator-Based Science), have successfully developed a technology to mass-produce the artificial element Astatine (At).
The results of this research are expected to greatly contribute to the development of cancer therapeutic drugs using alpha rays emitted by At.
Please read RIKEN's press release for details.

Research details page (Japanese Only):
https://www.riken.jp/press/2023/20230831_3/index.html